Myomo

Myomo Net Debt / EBITDA

The Net Debt to EBITDA of Myomo (MYO) as of Nov 6, 2026 is -0.07. In the previous year, Net Debt to EBITDA was 2.70 — a change of -102.50% (lower).

Net Debt / EBITDA

-0.07

YoY

-102.50%

Last updated:

Net Debt to EBITDA of Myomo is 2025 -0.07 . Net Debt to EBITDA of Myomo was 2024 2.70 . It decreases by -102.50% lower compared to the previous year.

The Myomo Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
0.50 USD
Jan 1, 2019
0.17 USD
Jan 1, 2020
1.09 USD
Jan 1, 2021
1.44 USD
Jan 1, 2022
0.45 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
2.70 USD
Jan 1, 2025
-0.07 USD
The Myomo Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.07-102.50%
2.70+168.94%
1.00+123.60%
0.45-68.78%
1.44+32.16%
1.09+548.11%
0.17-66.16%
0.50-74.85%
1.97-238.73%
-1.42+399.26%
-0.28-175.51%
0.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myomo Stock analysis

What does Myomo do? Myomo, Inc. generates revenue by selling its MyoPro product line, which consists of myoelectric-controlled upper limb braces designed for patients with neuromuscular disorders. The company directly sells these orthoses to patients and bills their insurance providers for coverage. The MyoPro enables users to control partially paralyzed limbs using their own muscle signals, supporting daily activities like eating and dressing. The target market includes adults and adolescents with conditions such as stroke, spinal cord injury, and brachial plexus injury. The MyoPro product line is marketed as a solution for functional improvement in upper limb paralysis, focusing on home and community use. Myomo’s devices are positioned to help patients regain independence in daily living tasks. Insurance reimbursement is a key revenue stream, with the company handling billing directly to insurers on behalf of patients. The primary customer segments are individuals with neuromuscular conditions requiring orthotic support for upper limb functionality. Myomo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myomo stock

Net Debt to EBITDA of Myomo is -0.07 in 2025.

Net Debt to EBITDA of Myomo changed from 2.70 to -0.07, representing a -102.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Myomo since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Myomo with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Myomo

All Key Metrics — Myomo